HHS nominee Alex Azar takes heat for raising insulin prices

Published



President Trump’s nominee to lead the Department of Health and Human Services told senators Wednesday he would fight drug makers that try to block competition from generic companies, but took heat from Democrats for raising drug prices for insulin while he was a pharma CEO.

Alex Azar was before the Senate Health, Education, Labor and Pensions Committee, which members of the committee used to remind Azar of his tenure as CEO of Eli Lilly’s U.S. division, during which that company raised the price of insulin.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.